IPCALAB.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 05:59):

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India...

Stats
Today's Volume	117 602
Average Volume	530 009
Market Cap	325.82B
EPS	INR0 ( 2024-02-13 )
Next earnings date	( INR5.60 ) 2024-05-27
Last Dividend	INR4.00 ( 2022-11-22 )
Next Dividend	INR0 ( N/A )
P/E	57.85
ATR14	INR1.323 (0.10%)

Volume Correlation

Long: 0.03 (neutral)

Short: 0.89 (strong)

Signal:(47.909) Same movement expected

Ipca Laboratories Limited Correlation

10 Most Positive Correlations
ALLCARGO.NS	0.878
RAJVIR.NS	0.838
AJRINFRA.NS	0.808
KHAITANLTD.NS	0.801

10 Most Negative Correlations
FOCUS.NS	-0.833
AGI.NS	-0.82
BANCOINDIA.NS	-0.816
KOVAI.NS	-0.812
MAYURUNIQ.NS	-0.81
MEGH.NS	-0.804
HILTON.NS	-0.804
FINCABLES.NS	-0.802
BECTORFOOD.NS	-0.802
SUPERHOUSE.NS	-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ipca Laboratories Limited Correlation - Currency/Commodity

0.56
( weak )

0.62
( weak )

-0.72
( moderate negative )

-0.11
( neutral )

-0.19
( neutral )

0.28
( neutral )

Ipca Laboratories Limited Financials

Annual	2022
Revenue:	INR62.44B
Gross Profit:	INR39.38B (63.06 %)
EPS:	INR18.58

FY	2022
Revenue:	INR62.44B
Gross Profit:	INR39.38B (63.06 %)
EPS:	INR18.58

FY	2022
Revenue:	INR57.66B
Gross Profit:	INR36.60B (63.48 %)
EPS:	INR34.85

FY	2021
Revenue:	INR53.41B
Gross Profit:	INR35.39B (66.27 %)
EPS:	INR45.01

Financial Reports:

No articles found.

Ipca Laboratories Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ipca Laboratories Limited Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.59 - low (19.38%) | Divividend Growth Potential Score: 1.867 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.150	1999-11-24
Last Dividend	INR4.00	2022-11-22
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	40	--
Total Paid Out	INR32.15	--
Avg. Dividend % Per Year	0.20%	--
Score	1.8	--
Div. Sustainability Score	3.59
Div.Growth Potential Score	1.867
Div. Directional Score	2.73	--

Next Divdend (Est)
(2024-11-15)

INR0 Estimate 0.00 %

Dividend Stability

0.08 Very Bad

Dividend Score

1.80

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.500	0.14%
2019	INR1.500	0.37%
2020	INR6.50	1.14%
2021	INR4.00	0.37%
2022	INR4.00	0.37%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHYAMMETL.NS	Dividend Junior	2023-06-05	Semi-Annually	4	0.70%
MATRIMONY.NS	Dividend Junior	2023-08-03	Annually	7	0.41%
GRWRHITECH.NS	Dividend Junior	2023-09-20	Semi-Annually	3	0.88%
BANDHANBNK.NS	Dividend Junior	2023-08-11	Sporadic	7	0.20%
PPL.NS	Dividend Junior	2023-09-18	Annually	6	0.62%
JWL.NS	Dividend Junior	2023-09-12	Insufficient data to determine frequency	2	0.17%
DSSL.NS	Dividend Junior	2023-08-23	Annually	6	0.34%
ACE.NS	Dividend Junior	2023-08-17	Annually	18	0.23%
STARPAPER.NS	Dividend Junior	2023-09-15	Sporadic	22	1.19%
MSUMI.NS	Dividend Junior	2023-08-09	Annually	3	0.60%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0785	1.500	8.43	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.126	1.500	9.71	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	7.15	1.000	8.46	8.46	[3 - 30]
operatingCashFlowPerShareTTM	25.91	2.00	1.364	2.73	[0 - 30]
freeCashFlowPerShareTTM	25.91	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.655	1.000	2.42	2.42	[0.2 - 0.8]
operatingProfitMarginTTM	0.127	1.000	9.47	9.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	59.17	1.000	4.12	0	[1 - 100]
returnOnEquityTTM	0.126	2.50	9.81	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	25.91	2.00	1.364	10.00	[0 - 30]
dividendYielPercentageTTM	0.152	1.500	6.20	0	[0 - 0.4]
operatingCashFlowPerShareTTM	25.91	2.00	1.364	2.73	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.267	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0915	1.000	-0.213	0	[0.1 - 0.5]
Total Score				1.867

Ipca Laboratories Limited

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.